
Table of Contents

Introduction to the Symposium 1
LIONEL MANDELL

PART 1 – Antimicrobial Chemotherapy

Antimicrobial Chemotherapy – Today 7
JOHN DAVID WILLIAMS

Antimicrobial Chemotherapy – Tomorrow 12
HARTMUT LODE

PART 2 – Pre-clinical

Pre-clinical Microbiology – Streptococcus Pneumoniae 21
REGINE HAKENBECK

Pre-clinical Microbiology – Gram-positive Cocci 27
SILVANO ESPOSITO

Pre-clinical Microbiology – Atypical Organisms 31
CÉCILE M. BÉBÉAR

Pre-clinical Microbiology – Summary I 36
BERND WIEDEMANN

Pre-clinical Microbiology – Mycobacteria 37
STEPHEN H. GILLESPIE

In-vitro Activity of Moxifloxacin [Bay 12-8039], an 8-methoxy Quinolone,
Compared to Other Fluoroquinolones Against Anaerobic Bacteria 43
ELLIE GOLDSTEIN

Pre-clinical Microbiology – Fastidious Gram-negative Bacteria 49
ADOLF BAUERNFEIND

Pre-clinical Microbiology – Respiratory Tract Infections Susceptibility Survey – USA	54
DANIEL SAHM	
Pre-clinical Microbiology – Respiratory Tract Infections Susceptibility Survey – Europe	59
DAVID FELMINGHAM	
Pre-clinical Microbiology – Respiratory Tract Infections Susceptibility Survey – Japan	67
KAZUNORI TOMONO	
Mechanisms of Fluoroquinolone Action and Resistance	75
KARL DRLICA	
Pre-clinical Microbiology – Summary II	84
BERND WIEDEMANN	
PART 3 – Pharmacology	
Pharmacokinetics and Pharmacodynamics of Antimicrobials	89
RICHARD WISE	
Mini-Reviews – Pharmacokinetics/Pharmacodynamics (PK/PD)	94
JEROME J. SCHENTAG	
In vitro Models as Predictors of the Antimicrobial Effect of Moxifloxacin and Other Fluoroquinolones	98
STEPHEN ZINNER	
In vitro Models of Infection – Pharmacokinetic/Pharmacodynamic Correlates	104
ALASDAIR P. MCGOWAN	
Animal Model Experiences with Moxifloxacin	111
JAMES M. STECKELBERG	
Current Thinking About Pharmacokinetics and Pharmacodynamics of Antimicrobials	118
JOHN TURNIDGE	
Pharmacology of Moxifloxacin – Absorption, Distribution, Metabolism and Excretion	122
CARL ERIK NORD	
Antimicrobial Drug-Drug Interactions – Focus on Fluoroquinolones	127
GARY E. STEIN	

Pharmacology – Tissue Distribution	130
ETHAN RUBINSTEIN	

Fluoroquinolones Phototoxicity – Moxifloxacin in Context	134
JAMES FERGUSON	

Fluoroquinolone Safety and Tolerability	138
PETER BALL	

PART 4 – Clinical Needs in the Millenium

Clinical Needs in the Millenium – Community Acquired Pneumonia . . .	147
PAUL LÉOPHONTE	

Clinical Needs in the Millenium – Pneumonia – The Role of Moxifloxacin	154
MARTIN SPRINGSKLEE	

Clinical Needs in the Millenium – Acute Exacerbations of Chronic Bronchitis	159
ROBERT WILSON	

Clinical Needs in the Millenium – Acute Exacerbations of Chronic Bronchitis – The Role of Moxifloxacin	165
DEBORAH CHURCH	

Clinical Needs in the Millenium – Rhinosinusitis	170
VALERIE J. LUND	

Clinical Needs in the Millenium – Rhinosinusitis – The Role of Moxifloxacin	175
BARBARA HAMPEL	

Discussion on Clinical Needs in the Millenium	179
---	-----

PART 5 – Round Table Discussion

Round Table Discussion – Introduction	185
---	-----

Round Table Discussion – Hospital Issues	186
--	-----

Round Table Discussion – Community Issues	191
---	-----

First International Moxifloxacin Symposium

Berlin, 1999

Mandell, L. (Ed.)

2000, XIII, 191 p., Hardcover

ISBN: 978-3-540-66476-5